David Allen, National University of Singapore, Yong Loo Lin School of Medicine

Biography:

Associate Professor David Allen attended Rice University in Houston, Texas before receiving his M.D. with honours from Southwestern Medical School in Dallas, Texas. He completed Internal Medicine residency and Infectious Diseases specialty training in New York Hospital/Cornell University Medical Center (CUMC) in New York City. David was Visiting Investigator at Rockefeller University and an Assistant Professor in the CUMC Division of Infectious Diseases when he was recruited to Singapore to establish an Infectious Disease training program and become the first Infectious Diseases Head of Department in the CDC Singapore (now NCID). Currently, David is Associate Vice President (Health Information and Transformation), NUS; Associate Professor in the Yong Loo Lin School of Medicine, NUS; Senior Consultant, Division of Infectious Diseases, NUH and Visiting Senior Consultant, NCID, Singapore.

ZP Therapeutics: COVID-19 Vaccine Boosters: Controversies and Recommendations

Abstract:

Despite the successes of vaccines, concerns remain about the possibility of reinfection, especially due to the emergence of new variants of concern (VOCs). Discussions around vaccine boosters have become key topics to manage COVID-19 infections. Debates are still around on which type of vaccines are best for whom, what timeline for booster strategies will best be suited to each individual country, and best practice for efficient execution. Zuellig Pharma (ZP) is one of the largest healthcare service groups in Asia dedicated to providing progressive and innovative solutions to meet changing healthcare needs. Zuellig Pharma is committed to compliance, quality, and strives towards the mission of making healthcare more accessible in Asia, especially now with COVID-19 vaccines.